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Focal segmental glomerular sclerosis (FSGS) is a major renal
complication of mitochondrial (mt) cytopathies. The present
study was designed to investigate the possibility of mtDNA
lesion accumulation in podocytes, which are a primary
pathogenic site of FSGS, during the development of
glomerulopathy in puromycin aminonucleoside nephrosis
(PAN). Two renal pathological phases of PAN, nephrosis
phase and FSGS phase were studied. We investigated the
expression of mt proteins, the copy number of a 4834
base-pair deletion (del-mtDNA), and total mtDNA content by
real-time polymerase chain reaction, as well as the mRNA
expression levels of the mt transcription factor A (mtTFA) and
the nuclear respiratory factor-1 (NRF-1) in glomeruli. The
mtDNA encoded cytochrome c oxidase subunit I (COX I)
protein level was identical to control in nephrosis phase,
however, a 45% reduction was seen in FSGS phase.
Intraglomerular del-mtDNA was 16–21 times higher than
controls in both phases, but the proportion of this mutation
was o1% of total mtDNA. The copy number of total mtDNA
at nephrosis phase increased up to 241%, whereas, it
decreased to 34% at FSGS phase in glomeruli. The mRNA
expression of both mtTFA and NRF-1 was upregulated at
nephrosis phase, but mtTFA was downregulated at FSGS
phase. A reduction in mtDNA copy number resulted in
reduced levels of COX I in glomeruli at FSGS phase,
suggesting that mt dysfunction by mtDNA depletion
potentially plays a key role in the pathogenesis of FSGS
in PAN.
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Mitochondria are essential intracellular organelles that have a
major role in energy production by ATP synthesis through
oxidative phosphorylation (OXPHOS) and play a key role in
apoptosis. Each mitochondrion has its own DNA, which is
the only extra nuclear genome in eukaryotes. The mitochon-
drial DNA (mtDNA) encodes for 13 structural genes of
OXPHOS enzymes, two ribosomal RNAs, and 22 transfer
RNAs.1 The mtDNA is prone to oxidative stress, since it
apparently lacks histone-like coverage and is localized closely
to the inner mt membrane, a major site of reactive oxygen
species (ROS) in cells. Moreover, mitochondria have an
incompetent DNA repair system contributing to more than a
10-fold higher mutation rate than nuclear DNA.2,3
Mitochondria are involved in many kinds of diseases and
progressive disease processes in a variety of tissue types.
Recently, the glomerular involvement of an A-to-G transition
at mtDNA position 3243 in the gene for tRNALeu(UUR) that
presented with proteinuria and focal segmental glomerular
sclerosis (FSGS) was reported.4,5 We also reported that two
additional cases of an A-to-G transition at mtDNA position
3243 based on screening of maternally inherited, familial
FSGS cases. In these circumstances, the mutations had
accumulated to levels above 80% of mtDNA within renal
biopsy specimens, highlighting tissue specificity of mt disease
states.6 The importance of mtDNA sequence status to kidney
function is also underscored by the recent production of a
mouse model carrying mutant mtDNA with a 4696-bp
deletion, which suffered FSGS and died within 6 months due
to renal failure. In this mouse, the kidney carried the greatest
accumulation of the mtDNA deletion of any organ.7
Puromycin aminonucleoside nephrosis (PAN) is the best-
described animal model of glomerular disease. The patho-
logical phenotype is a minimal change nephrotic syndrome
by a single injection of puromycin aminonucleoside (PA),
and further injections of PA introduces specific FSGS lesions.8
Previous studies have suggested that these glomerular injuries
are induced by ROS because antioxidants reduce proteinuria
and inhibit foot-process effacement in the PAN model.9
However recently, others have suggested that antioxidants
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protect only against the foot process effacement, but do not
change the damage that occurs in podocyte cell bodies and
other major processes.10 Furthermore, podocyte depletion, or
detachment from glomerular basement membrane (GBM), is
a crucial event for the formation of FSGS lesions.11 In the
kidney of PAN, the reduction of respiratory chain enzymatic
activities, oxygen consumption, and the swelling of renal
tubular mitochondria have been observed.12–16 Podocytes are
highly differentiated cells that lose mitotic activity in fully
developed kidneys.17 This characteristic loss of mitotic
activity is identical to neuronal cells and muscular cells,
which are regarded as major sites for the accumulation of
somatic mtDNA mutations. The cell body of a podocyte
contains a prominent nucleus, a well-developed Golgi system,
abundant rough and smooth endoplasmic reticulum, pro-
minent lysosomes, and a prolific amount of mitochondria.
Podocytes demand a high energy supply to maintain various
cellular functions including the organization of cytoskeletal
and extracellular matrix proteins. PA administration causes
podocyte blebbing and rounding and reduces cell adhesion to
plastic.18 Until now, there was little information about
potential mt changes within podocytes and its role in
glomerular damage of PAN.
The present study was designed to investigate accumula-
tions of mtDNA alternations in glomeruli, especially
podocytes, during the disease course of PAN, which might
have a pathogenic role for FSGS in PAN.
RESULTS
Proteinuria and histological changes
Urinary protein excretion increased after 3 days and
continued to increase until the 7th day in PAN rats. The
urinary protein excretion declined, but persisted above
normal at 28 days after PA injection. A significant amount
of proteinuria continued during all terms after the second PA
treatment (Figure 1a).
Light microscopic examination of the kidney sections
revealed no histological changes in 1 and 5 days after PA
injection. Pseudocyst formation of podocyte, small segmental
proliferation with matrix expansion and adhesions between
the glomerular tuft and Bowman’s capsule were observed, but
the certain FSGS lesions were less than 1% at 10 days after
injection (nephrosis phase). The proportion of FSGS lesions
(Figure 1b), or global sclerosis lesions increased gradually at
52 days after initial injection (10 days after last injection).
Both FSGS lesions and global sclerosis lesions were observed
14.075.3%, 1.271.3%, respectively. At 77 days after initial
injection (FSGS phase), FSGS lesions and global sclerosis
lesions were observed 45.1712.3%, 17.8720.2%, respec-
tively. Focal interstitial mononuclear cell infiltrate and tubu-
lar atrophy were also present at FSGS phase. While foot process
effacement was seen at nephrosis phase glomeruli by electron
microscopy, the hypertrophied podocyte, showing abundant
cytoplasm, increased absorption droplets, variable degrees
of effacement of foot processes, and the mitochondria in the
hypertrophied podocyte were enlarged and had a few or
incomplete cristae at FSGS phase (Figure 1c).
Mitochondrial protein changes
Histochemical staining for cytochrome c oxidase (COX)
activity displayed a reduction of COX activity that was
observed within small areas of tubules at nephrosis phase as
well as in broader areas of later phase kidney sections.
However, it was difficult to compare COX activities in
glomeruli by COX staining, because COX activities in
glomeruli of both phases and control rats were very weak
(data not shown).
When compared to controls, glomerular mitochondria
stained with anti-cytochrome c oxidase subunit I (COX I)
antibody and anti-cytochrome c oxidase subunit IV (COX
IV) antibody were identical at nephrosis phase (Figure 2a–c
and g–i). The glomerular mitochondria stained with anti-
COX IV antibody was also identical to controls at FSGS phase
(Figure 2f), However, anti-COX I antibody staining
decreased at FSGS phase (Figure 2d) and the intense staining
of COX I protein was seen to be reduced with higher
magnification (Figure 2e) when compared to controls or
nephrosis phase mitochondria (Figure 2b and h).
Figure 3 shows the result of Western blotting assays of
COX I and COX IV proteins extracted from isolated
glomerular mitochondria. The proportion of COX I to
COX IV (COX I/COX IV) was identical at nephrosis phase
(118724%) and day 52 (92734%). However, a 45%
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Figure 1 | (a) Proteinuria and histological changes. Twenty
four-hour urinary protein excretion in the PAN rats (K) and control
rats (m). Values are expressed as mean7s.d. * indicates Po0.05 for
age-matched control. (b) Typical morphological changes of PAN rat
FSGS phase (periodic acid-Schiff stain, Original magnification  160).
Segmental sclerosis and hyalinosis lesion were observed (arrow).
(c) Electron micrograph of glomerulus at FSGS phase. Foot processes
of podocytes were shown variable degrees of fusion and effacement.
A portion of the mitochondria profiles in podocytes were enlarged
and had a few or incomplete cristae (arrow). (Original magnifications
 5000).
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reduction of COX I/COX IV was observed at FSGS phase
(55726%) and it was significantly decreased when compared
to those at nephrosis phase. (Po0.001).
Mitochondrial DNA changes
The copy-number ratio of del-mtDNA among total mtDNA
was 16 times higher than age-matched controls at nephrosis
phase in glomerular-extracted DNA. While the proportion of
del-mtDNA among total mtDNA increased to 21 times more
than age-matched controls at FSGS phase, it was only
5.9679.65 108% thereafter. Although del-mtDNA accu-
mulated within glomeruli, the proportion was o1% of total
mtDNA for both phases.
Using DNA from kidney cortex, the copy-number ratio of
mtDNA among nuclear DNA (mtDNA/18SrRNA) at 1 day
(92715%) and 5 days (106714%) after PA injection were
identical. Mitochondrial DNA/18SrRNA was significantly
increased at nephrosis phase (163733%) comparing to day
1 rats (P¼ 0.013), or day 5 rats (P¼ 0.032), respectively
(Figure 4a). Mitochondrial DNA/18SrRNA was decreased at
day 52, and significantly decreased at FSGS phase (62719%)
comparing to day 1 rats (P¼ 0.049), day 5 rats (P¼ 0.011),
or nephrosis phase rats (Po0.001), respectively (Figure 4a).
Using DNA extracted from isolated glomeruli, these
changes were more obvious. Mitochondrial DNA/18SrRNA
was significantly increased at nephrosis phase (241780%)
when compared to day 1 rats (P¼ 0.022) (Figure 4b).
Mitochondrial DNA/18SrRNA was significantly decreased at
day 52 (70717%) when compared to nephrosis phase rats
(P¼ 0.002). At FSGS phase, it was further decreased
(3478%) when compared to day 1 rats (P¼ 0.002), day 5
rats (Po0.001), nephrosis phase rats (Po0.001), and day 52
rats (P¼ 0.003), respectively (Figure 4b). Figure 5 shows a
picture of fluorescence in situ hybridization (FISH) for
mtDNA in the glomerulus of a FSGS phase kidney section
and control. The decreased staining intensity of mtDNA
molecules was observed in the glomerulus at FSGS phase.
Podocyte changes
The average number of Wilms’ tumor protein-1 (WT-1)-
positive cells in glomeruli was 8.9070.34/glomerulus in
controls, 8.0270.82/glomerulus at day 52, and 6.3270.43/
glomerulus at FSGS phase. Thus, it was reduced by
approximately 10 and 30% in glomeruli from day 52 and
FSGS phase rats, respectively. Some podocytes show enlarged
nucleus and diminished staining of anti-WT-1 antibody in
FSGS phase glomerulus.
Expression of mtDNA replication molecules
Figure 6 shows mt transcription factor A (mtTFA) mRNA
and nuclear respiratory factor-1 (NRF-1) mRNA expression
at 1 day after PA injection, at nephrosis phase, at 52 days, and
at FSGS phase by reverse transcription-polymerase chain
reaction (RT-PCR). Intraglomerular mtTFA mRNA was
upregulated at nephrosis phase and was slightly upregulated
at 52 days when compared to day 1 rats after PA injection and
controls. However, it was downregulated at FSGS phase when
compared to nephrosis phase, at 52 days, and control rats.
The upregulation of NRF-1 mRNA was observed in nephrosis
phase and in 52 days rats, but it was not observed in day 1,
FSGS phase, or control rats.
DISCUSSION
While a relationship between PAN and tubular mt dysfunc-
tion has been reported previously,12–16 this is the first
description of specific mt changes, especially mtDNA
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Figure 3 | Proportion of intraglomerular COX I/COX IV proteins.
The proportions of COX I/COX IV in glomeruli of PAN, which were
quantified as a percentage of age-matched control values. A
significant COX I/COX IV reduction was observed at FSGS phase.
Values are expressed as mean7s.d. * indicates Po0.05.
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Figure 2 | Glomerular distribution of COX proteins. (a and b)
Intraglomerular COX I protein distribution and COX IV (c) at nephrosis
phase, (d) COX I, and (e) COX IV at FSGS phase, and (g and h) COX I
and (i) COX IV in controls, and nuclei stained by 4,6-diamidino-2-
phenylindole in all sections. Intraglomerular COX I protein distribu-
tion at nephrosis phase was identical to controls, however, segmental
reduction of intraglomerular COX I protein distribution was observed,
especially in top of right and bottom of left at FSGS phase. Where as,
intraglomerular COX IV protein distribution was identical in all
sections. Original magnifications: a, c, d, f, g, and i:  40; b, e,
and h:  100.
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alterations, within glomeruli of PAN. In this study, we
observed that intraglomerular COX I/COX IV ratios
decreased at FSGS phase, whereas the intraglomerular COX
I/COX IV ratio was not observed to change at the nephrosis
phase. However, the reduction of the intraglomerular
mtDNA-encoded protein, COX I, suggests that there is either
an induction of mtDNA damage or a reduction in mtDNA
copy number during the progression of PAN. Moreover, this
possibility is underscored by the observation of abnormally
hypertrophied mitochondria in the podocytes at FSGS phase.
These results suggest that FSGS lesions in PAN might be
induced by mt dysfunction in the podocyte, perhaps as a
result of mtDNA alterations. There have been several
previous reports describing mt dysfunction and/or mtDNA
changes in glomerular diseases. Kakimoto et al.19 reported
the accumulation of oxidative damage of mtDNA in the
kidney of streptozotocin-induced diabetes rats, and Holtho-
fer et al.20 reported mitochondrially encoded respiratory
chain complex downregulation in the isolated glomeruli of
patients with the congenital nephrotic syndrome of the
Finnish type. Several authors reported that patients with an
A-to-G transition at mtDNA position 3243 showed protein-
uria with FSGS lesions.4–6 Furthermore, mice with mutant
mtDNA carrying a 4696-bp deletion, suffered FSGS lesions,
and died within 6 months due to renal failure.7
The mechanism of glomerular injury and FSGS lesion
induced by PA injection has not been fully investigated. Yet,
previous studies have suggested that an increase in the
production of ROS in glomeruli is correlative.21 Mitochon-
drial DNA is prone to oxidative stress by ROS, and is more
easily affected than nuclear DNA, since it lacks a histone-like
coverage and has a limited DNA repair system.2 Therefore,
we consider the possibility that mt dysfunction might occur
by the accumulation of mtDNA mutations due to excessive
ROS in glomeruli caused by PA administration. Several
reports have suggested that excessive ROS production results
in the accumulation of mtDNA with a 4834-bp deletion
mutation spanning mtDNA nucleotide pairs (np)
a b
Figure 5 | MtDNA distribution in glomeruli. Fluorescence in situ
Hybridization for mtDNA in glomerulus at (a) FSGS phase (b) and
age-matched control. The red signals represented mtDNA molecules,
and the blue signals represented the nuclei by DAPI stain. MtDNA
signals in glomerulus were decreased at FSGS phase, compared to
age-matched control. Original magnifications of a, b:  100.
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Figure 6 | Expression of mitochondrial DNA (mtDNA) replication
molecules. The expressions of mtTFA and NRF-1 and GAPDH mRNA
in the glomeruli at day 1 after PA injection, at nephrosis phase, at 52
days and at FSGS phase were examined by reverse transcription-
polymerase chain reaction (RT-PCR). The mRNA expression of mtTFA
was upregulated at nephrosis phase and was slightly upregulated at
52 days, and downregulated at FSGS phase, compared to each
control. The upregulation of NRF-1 mRNA was observed at nephrosis
phase and at 52 days, but it was not observed in day 1 and FSGS
phase PAN rats and each control rats.
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Figure 4 | MtDNA copy-number changes. The proportions of mtDNA copy number to 18SrRNA genome (nuclear DNA) copy number (mtDNA/
18SrRNA) quantified as a percentage of age-matched control values in DNA from (a) kidney cortex and isolated (b) glomeruli were shown. DNA
from kidney cortex, mtDNA/18SrRNA was constant until 5 days after PA injection, but a significant increase of mtDNA/18SrRNA was observed at
nephrosis phase. (a) Furthermore, a significant decrease of mtDNA/18SrRNA was observed at FSGS phase. This change was enhanced in DNA
from isolated glomeruli. (b) Sixty-six percent reduction of mtDNA copy number was observed at FSGS phase. Values are expressed as
mean7s.d. *Po0.05 compared to each phase of rats. #Po0.05 compared to age-matched controls.
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8103–12 937.19,22,23 Previously, we reported that mtDNA with
a deletion mutation also accumulates in the glomeruli of
patients with FSGS, but the proportion of this deletion
among total mtDNA was o1%.6 In this study, we also
observed that the relative level of the 4834-bp deleted
mtDNA increased up to 16-fold at nephrosis phase, when
compared to control rats, and 21-fold at FSGS phase in
glomeruli of PAN rats. However, the proportion of deleted
mtDNA among total mtDNA content was o1% in the
glomeruli of PAN rats. Hayashi et al. reported that an
accumulation of mutant mtDNA to a level of at least 60% of
total is required for mt dysfunction.24–26 Consequently, even
though an accumulation of deleted mtDNA in the glomeruli
of PAN rats was observed, this was perhaps not sufficient to
account for alterations of the observed indicators of mt
dysfunction.
We have demonstrated that mtDNA copy number in the
kidney cortex increased about 163% at the nephrosis phase,
which was identical to controls at 52 days, and decreased to
about 62% at FSGS phase. Furthermore, in the DNA
extracted from glomeruli, mtDNA copy number increased
up to 241% of controls at the nephrosis phase, decreased to
70% of controls at 52 days, and further decreased to 34% of
controls at the FSGS phase. Each cell has about 103–105
copies of mtDNA, and mtDNA copy number seems to
parallel cellular energy demand. This increase of mtDNA
copy number at the nephrosis phase might be a result of
additional energy required to protect or repair glomerular
cellular function from PA injury. However, this phenomenon
could potentially be abolished by multiple injections of PA,
resulting in the depletion of mtDNA and leading to mt
dysfunction. Solin et al.27 has reported that the reduction of
mtDNA copy number in the kidney cortex was the main
cause of mt dysfunction in congenital nephrotic syndrome of
the Finnish type.
Podocytes have the most abundant mitochondria among
glomerular cells.13 Kim et al.28 has suggested that multiple
injections of PA induced podocyte depletion in glomeruli due
to cell detachment from GBM. Thus, there was a possibility
that the intraglomerular mtDNA copy-number reduction
observed in this study might be a consequence of podocyte
depletion at the FSGS phase. The number of podocytes
within the glomerulus observed in this study were almost
equivalent to previous data described by Kim et al.28
Although, the number of WT-1-positive cells decreased by
10% at day 52, the copy number of intraglomerular mtDNA
was reduced by 30%. Furthermore, the copy number of
intraglomerular mtDNA was reduced by more than 65%,
while the number of WT-1-positive cells in glomeruli was
reduced by only 30% at FSGS phase. Recently, Wang et al.29
reported that podocytes covering the sclerotic segments in
human FSGS lesions diminished WT-1 staining. In this study,
we also observed podocytes diminished WT-1 staining.
Consequently, the podocyte number at FSGS phase during
this study might be an underestimate of the true number of
podocytes due to the potential loss of anti-WT-1 antibody
staining. Otherwise, the predominant reduction of mtDNA-
encoded protein (COX I) than nuclear DNA-encoded protein
(COX IV) in glomeruli was not due to podocyte depletion
but to mtDNA depletion at FSGS phase. Consequently, mt
dysfunction due to mtDNA depletion has a key role in the
reduction of podocyte cell viability and adhesive activity,
which consequently results in FSGS lesions during the disease
course of PAN.
Several different molecules are involved in mtDNA
biogenesis. Mitochondrial transcription factor A directly
binds mtDNA, and NRF-1, is an epistatic molecule of
mtTFA, and both are recognized as key molecules of mtDNA
biogenesis.30 In this study, we observed that the mRNA
expression of mtTFA and NRF-1 are upregulated in glomeruli
at the nephrosis phase and at 52 days (10 days after the last
PA injection) of PAN. Recently, Nisoli et al.31 described that
nitric oxide (NO), which is a ROS, triggered mt biogenesis
through the upregulation of both mtTFA and NRF-1.
Increased NO production was reported in the kidney of
acute PAN rat (nephrosis phase),32 whereas downregulation
of NO synthesis was observed in the kidney of chronic PAN
rat (FSGS phase).33 Consequently, it is suggested that the
enhanced mtDNA biogenesis in glomeruli at nephrosis phase
and the decrease of mtDNA copy number at FSGS phase is a
direct effect of NO changes induced by PA injection. Indeed
in this study, at 52 days, both mtTFA and NRF-1 mRNA
levels were observed to be upregulated, and in contrast,
intraglomerular mtDNA copy number decreased. Yet in
mtDNA depleted cells, both NRF-1 and mtTFA mRNA were
upregulated,34 whereas both NRF-1 and mtTFA protein levels
decreased.35 Further studies are needed to probe the
relationship and serial changes between NO production,
mRNA, and the expression of mt proteins in PAN.
In summary, we observed that the formation of FSGS
lesions are accompanied by intraglomerular mtDNA-encoded
protein reduction and intraglomerular mtDNA depletion
with downregulation of mRNA expression of mtTFA and
NRF-1. Additional studies are needed to clarify the role of
regulatory factors in mtDNA biogenesis, as well as to test the
potential therapeutic effects of antioxidants or angiotensin
blockade treatment on mt alterations in PAN, and to detail
the pathological mechanism of mt dysfunction on podocyte
function.
MATERIALS AND METHODS
Animals
Male Sprague–Dawley rats, weighing 200–300 g (Charles River Japan
Inc., Yokohama, Japan), were used for this study. They were fed
normal rat chow and water ad libitum. All experiments were
performed according to the Guide for the Care and Use of
Laboratory Animals in University of Tsukuba.
Induction of PAN
We induced two renal pathological phases of PAN. Sprague–Dawley
rats either received a single injection of PA (Wako, Tokyo, Japan),
15 mg/100 g, intraperitonally, for nephrosis phase rats, and/or they
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received multiple injections of PA, 15 mg/100 g at initial day and
5 mg/100 g at days 28, 35, and 42, intraperitonally, for FSGS phase
rats. Control rats were injected with 0.9% saline at the same time.
Proteinuria was assessed by the sulfosalicylic acid method. The PA-
injected rats and control rats were killed at day 1 (n¼ 3), 5 (n¼ 3),
10 (n¼ 5, nephrosis phase), 52 (n¼ 5, 10 days after last PA
injection), and 77 (n¼ 5, FSGS phase), respectively.
Kidney tissue preparation
For the histological examination, kidney sections were placed in the
OCT compound (Tissue-Tek; Sakura Finetechnical, Tokyo, Japan)
and stored at 801C until use, or fixed in 10% neutral-buffered
formalin and blocked in paraffin wax and stained with hematox-
ylin–eosin (H&E), periodic acid-Schiff (PAS) reagent or periodic
acid methenamine silver reagent. For the evaluation of the
glomerular changes, we observed at least 100 glomeruli in a single
section, and counted the number of abnormal glomeruli including
global sclerosis, adhesion, and segmental sclerotic lesions. For the
electron microscopy, kidney sections were fixed in 2.5% glutar-
aldehyde, postfixed in 1% osmium and embedded in epoxy resin.
Ultrathin sections were stained with uranyl acetate, and examined
with 100CX electron microscopy (JEOL, Tokyo, Japan).
Histochemistry and immunofluorescence
To examine the activity of COX in kidney, 3 mm-thick cryostat
sections were incubated with the reagent consisting 0.1 M. sodium
acetate (pH 5.6), 0.1% MnCl2, 0.001% H2O2, 3,3
0diaminobenzidine
tetrahydrochrolide 60 mg at 371C for 20 min. The sections were
washed with water and then stained with 1% CuSO4 at room
temperature for 5 min.
To examine the expression of COX subunits, we used a mouse
monoclonal antibody to COX I, which is a mtDNA encoded protein,
and a mouse monoclonal antibody to COX IV, which is a nuclear
DNA-encoded protein, as primary antibodies. Cryostat sections
(3mm thick) were fixed with 4% paraformaldehyde and then
blocked with 10% normal goat serum. The sections were incubated
with the primary antibodies over night at 41C. Alexa Fluor 488-
conjugated, goat-anti-mouse immunoglobulin G-specific antibody
(Molecular Probe Inc., Eugene, OR, USA) was used as secondary
antibody. The sections were incubated with the secondary antibody
at room temperature for 90 min, followed by briefly counterstaining
with 4,6-diamidino-2-phenylindole. The immunofluorescence sec-
tions were observed using a microscope equipped with an
epifluorescence system (Olympus, Tokyo, Japan). The fluorescence
images were acquired using a digital camera system (ORCAs;
Hamamatsu photonics, Hamamatsu, Japan).
To recognize podocytes morphological alterations, we stained
WT-1-positive cells in glomeruli. Paraffin-embedded sections (2 mm
thick) were used and stained as previously reported.29 For the
evaluation of the podocyte amount within glomeruli, we scanned at
least 50 glomeruli in a single section, and counted the number of the
WT-1-positive cells.
Isolation of glomeruli and glomerular mitochondria
The kidney cortex was finely minced and sieved through sequential
sieves of 150, 125, and 75 mm pore size. The purity of the obtained
glomeruli was over 90% by stereoscopic microscope. The isolation
of mitochondria from glomeruli was carried out as in a previously
described method.36 The glomerular homogenates were centrifuged
and the supernatants were collected, and used as the mt fraction of
glomeruli.
Western blotting assay
The mt fractions of glomeruli were resuspended in a buffer
consisting of 50 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate,
10% glycerol, and bromophenol blue. The samples were separated
on 12.5% SDS-polyacrylamide gel electrophoresis under reducing
conditions, and then immunoblotted with monoclonal anti-COX I
and anti-COX IV antibodies. The blots were incubated with the
peroxidase-conjugated anti-mouse IgG (Zymed Laboratories, Carl-
ton Court, San Francisco, CA, USA). The peroxidase signal was
enhanced using the ECL Pluss method (Amersham Biosciences
Corp., NJ, USA). The images were analyzed with the NIH image
analyzer program (National Institutes of Health, MD, USA). The
proportions of COX I to COX IV were quantified as a percentage of
age-matched controls.
Quantitative real-time PCR and reverse transcription-PCR
Total DNA was extracted from kidney cortex and isolated glomeruli
by DNeasy Tissue Kits (QIAGEN sciences, MD, USA). Total RNA
was extracted from isolated glomeruli by SV total RNA isolation
systems (Promega, Madison, WI, USA).
To examine the copy number of total mtDNA and 4834-bp
deletion spanning np 8103–12 937 of mtDNA (del-mtDNA) in the
kidney cortex and glomeruli, we employed a real-time PCR method
with ABI PRISM 7700 TaqMan PCR machine (Applied Biosystems,
Foster City, CA, USA). All primers (Table 1) were designed using
Primer Express software Ver.2.0 (Applied Biosystems). The amounts
of del-mtDNA, total mtDNA and 18SrRNA genome were calculated
with the sequence detector Ver.1.6.3 (Applied Biosystems). Total
mtDNA was corrected by simultaneous measurement of 18SrRNA
genome encoded by the nuclear DNA, proportions of mtDNA to
18SrRNA genome of PAN glomeruli or kidney cortex was quantified
as a percentage of age-matched controls. For the calibration,
a 702-bp mtDNA segment (np 1746–2447) and a 510-bp deleted
mtDNA segment (np 7936–13 272) and an 801-bp 18SrRNA genome
segment were amplified from a normal Sprague–Dawley rat kidney
DNA.
The RT-PCR was performed to determine the amount of mRNA
of transcript factor of mtDNA. The Dnase-treated glomerular RNA
Table 1 | PCR primer sets and probes
Target Oligonucleotide sequence
4834-bp deletion
of mtDNA
F 50-AAT TCA CAC ACC AAA AGG ACG A-30
R 50-TGG TGA CGA AGT AGA TGA TCC G-30
P FAM-AGC CCT AAT AAT CAC TTT AAT-MGB
Total mtDNA F 50-TAT TAG TGG CAT CGC CTG CC-30
R 50-GAC CCT CGT TTA GCC ATT CAT TC-30
P FAM-AAG GTA GGA TAA TCA CTT GTT C-MGB
18SrRNA F 50-TGC ATG GCC GTT CTT AGT TG-30
R 50-TAG CAT GCC GAG ATG CTC GTT-30
P FAM-TGG AGC GAT TTG TCT GGT TAA TTC CGA-MGB
mtTFA-cDNA F 50-TTG GGA TTG GGC ACA AGA AG-30
R 50-AAC CCG CAC GAA ACT GTC A-30
NRF-1-cDNA F 50-GGA GCA GGC GGG TGT AAG T-30
R 50-GTG AGC AGG AAA GCT GTC CC-30
F, forward; mtDNA, mitochondrial DNA; mtTFA, mitochondrial transcription factor A;
NRF-1, nuclear respiratory factor-1; P, primer; R, reverse.
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was reverse transcribed with Ready-To-GoTM T-Primed First-Strand
Kit (Amersham Biosciences). Primers were designed for mtTFA,
NRF-1, and glyceraldehyde-3-phosphate dehydrogenase (Table 1).
The PCR products were electrophoresed in 2% agarose gel. The
images were analyzed with the NIH image analyzer program.
Fluorescence in situ hybridization
To examine amount of the mtDNA in tissue, we used the mtDNA
FISH method. The probe specific for rarely deleted region of
mtDNA (np 293–6382) was generated by PCR and labeled with
ARES DNA-labeling kit (Molecular Probes Inc., Eugene, OR, USA).
Cryostat sections (3mm thick) were fixed with 4% paraformalde-
hyde, permeabilized with ethanol. The hybridization method was
carried out as in a previously described method.37 The sections were
counterstained with DAPI.
Statistical analysis
Values are presented as mean7s.d. Statistical analyses were
performed using analysis of Student’s t-test.
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